{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:41:40Z","timestamp":1790066500018,"version":"4.0.1"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Science & Engineering Research Board \u2212 Department of Science & Technology","award":["SERB-DST"],"award-info":[{"award-number":["SERB-DST"]}]},{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.biopha.2017.04.024","type":"journal-article","created":{"date-parts":[[2017,4,16]],"date-time":"2017-04-16T00:31:31Z","timestamp":1492302691000},"page":"752-759","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Neprilysin inhibitors: A new hope to halt the diabetic cardiovascular and renal complications?"],"prefix":"10.1016","volume":"90","author":[{"given":"Vajir","family":"Malek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil Bhanudas","family":"Gaikwad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2017.04.024_bib0005","series-title":"Global Health Estimates: Deaths by Cause, Age, Sex and Country, 2000\u20132012","author":"WHO World Health Organization","year":"2014"},{"key":"10.1016\/j.biopha.2017.04.024_bib0010","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1001\/jama.2014.15825","article-title":"Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial","volume":"312","author":"Muhlestein","year":"2014","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.biopha.2017.04.024_bib0015","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S2213-8587(14)70057-9","article-title":"Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study","volume":"2","author":"Li","year":"2014","journal-title":"Lancet Diab. Endocrinol."},{"key":"10.1016\/j.biopha.2017.04.024_bib0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/01.hjh.0000191244.91314.9d","article-title":"Blockade of the renin?angiotensin?aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes","volume":"24","author":"Burnier","year":"2006","journal-title":"J. Hypertens."},{"key":"10.1016\/j.biopha.2017.04.024_bib0025","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/ndt\/gfu269","article-title":"Neprilysin inhibition in chronic kidney disease","volume":"30","author":"Judge","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.biopha.2017.04.024_bib0030","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/ejhf.250","article-title":"Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances","volume":"17","author":"McMurray","year":"2015","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.biopha.2017.04.024_bib0035","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/hr.2009.74","article-title":"Devil and angel in the renin\u2013angiotensin system: ACE \u2013 angiotensin II \u2013 AT1 receptor axis vs. ACE2\u2013angiotensin-(1\u20137)?Mas receptor axis","volume":"32","author":"Iwai","year":"2009","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.biopha.2017.04.024_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/594361","article-title":"Protective role of the ACE2\/Ang-(1\u20139) axis in cardiovascular remodeling","volume":"2012","author":"Ocaranza","year":"2012","journal-title":"Int. J. Hypertens."},{"key":"10.1016\/j.biopha.2017.04.024_bib0045","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1111\/j.1742-4658.2011.08082.x","article-title":"Natriuretic peptide metabolism, clearance and degradation","volume":"278","author":"Potter","year":"2011","journal-title":"FEBS J."},{"key":"10.1016\/j.biopha.2017.04.024_bib0050","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11897-015-0270-8","article-title":"The role of neprilysin inhibitors in cardiovascular disease","volume":"12","author":"Mills","year":"2015","journal-title":"Curr. Heart Fail. Rep."},{"key":"10.1016\/j.biopha.2017.04.024_bib0055","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1161\/01.CIR.0000020500.77568.3C","article-title":"Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension results of the conduit hemodynamics of Omapatrilat international research study","volume":"105","author":"Mitchell","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2017.04.024_bib0060","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.pharmthera.2014.05.002","article-title":"Current role of neprilysin inhibitors in hypertension and heart failure","volume":"144","author":"von Lueder","year":"2014","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.biopha.2017.04.024_bib0065","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.biopha.2017.04.024_bib0070","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1524-6175.2002.01506.x","article-title":"The rise and fall of omapatrilat","volume":"4","author":"Pickering","year":"2002","journal-title":"J. Clin. Hypertens."},{"key":"10.1016\/j.biopha.2017.04.024_bib0075","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ahj.2004.09.056","article-title":"Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study","volume":"150","author":"Solomon","year":"2005","journal-title":"Am. Heart J."},{"key":"10.1016\/j.biopha.2017.04.024_bib0080","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/ejhf.474","article-title":"LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin\u2010induced diabetic mice","volume":"18","author":"Suematsu","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.biopha.2017.04.024_bib0085","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/ki.2015.107","article-title":"Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats","volume":"88","author":"Roksnoer","year":"2015","journal-title":"Kidney Int."},{"key":"10.1016\/j.biopha.2017.04.024_bib0090","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1042\/CS20160197","article-title":"Blood pressure-independent renoprotection in diabetic rats treated with AT1 receptor-neprilysin inhibition versus AT1 receptor blockade alone","volume":"30","author":"Roksnoer","year":"2016","journal-title":"Clin. Sci."},{"key":"10.1016\/j.biopha.2017.04.024_bib0095","doi-asserted-by":"crossref","first-page":"16S","DOI":"10.1016\/j.amjhyper.2004.08.004","article-title":"The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications","volume":"17","author":"Cooper","year":"2004","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.biopha.2017.04.024_bib0100","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1291\/hypres.31.921","article-title":"Comparison of the effects of telmisartan and olmesartan on home blood pressure, glucose, and lipid profiles in patients with hypertension, chronic heart failure, and metabolic syndrome","volume":"31","author":"Sasaki","year":"2008","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.biopha.2017.04.024_bib0105","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00041552-200105000-00005","article-title":"Proinflammatory actions of angiotensins","volume":"10","author":"Ruiz-Ortega","year":"2001","journal-title":"Curr. Opin. Nephrol. Hy."},{"key":"10.1016\/j.biopha.2017.04.024_bib0110","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/dom.12583","article-title":"Early renin\u00f6angiotensin system intervention is more beneficial than late intervention in delaying end\u00f6stage renal disease in patients with type 2 diabetes","volume":"18","author":"Schievink","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.biopha.2017.04.024_bib0115","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1161\/CIRCRESAHA.116.306923","article-title":"Molecular and cellular mechanisms of cardiovascular disorders in diabetes","volume":"118","author":"Shah","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.biopha.2017.04.024_bib0120","doi-asserted-by":"crossref","first-page":"202","DOI":"10.21037\/atm.2016.05.24","article-title":"Does renin angiotensin system blockade deserve preferred status over other anti-hypertensive medications for the treatment of people with diabetes?","volume":"4","author":"Barzilay","year":"2016","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.biopha.2017.04.024_bib0125","doi-asserted-by":"crossref","first-page":"S320","DOI":"10.2337\/dc11-s248","article-title":"RAS blockade for every diabetic patient: pro and con","volume":"34","author":"Ruilope","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2017.04.024_bib0130","doi-asserted-by":"crossref","first-page":"i438","DOI":"10.1136\/bmj.i438","article-title":"Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials","volume":"352","author":"Bangalore","year":"2016","journal-title":"Br. Med. J."},{"key":"10.1016\/j.biopha.2017.04.024_bib0135","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3390\/jcm4061325","article-title":"Horizon 2020 in diabetic kidney disease: the clinical trial pipeline for add-on therapies on top of renin angiotensin system blockade","volume":"4","author":"Perez-Gomez","year":"2015","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.biopha.2017.04.024_bib0140","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","article-title":"Aldosterone escape during blockade of the renin?angiotensin?aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate","volume":"47","author":"Schjoedt","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopha.2017.04.024_bib0145","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1517\/14656566.8.5.529","article-title":"Angiotensin II reactivation and aldosterone escape phenomena in renin\u2013angiotensin\u2013aldosterone system blockade: is oral renin inhibition the solution?","volume":"8","author":"Athyros","year":"2007","journal-title":"Exp. Opin. Pharmacother."},{"key":"10.1016\/j.biopha.2017.04.024_bib0150","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1016\/j.jacc.2007.09.021","article-title":"Natriuretic peptides","volume":"50","author":"Daniels","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2017.04.024_bib0155","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/00004872-199210000-00002","article-title":"Molecular biology and biochemistry of the natriuretic peptide system. II: Natriuretic peptide receptors","volume":"10","author":"Nakao","year":"1992","journal-title":"J. Hypertens."},{"key":"10.1016\/j.biopha.2017.04.024_bib0160","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/01.CIR.90.1.195","article-title":"Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure","volume":"90","author":"Yasue","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2017.04.024_bib0165","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40292-015-0112-5","article-title":"Angiotensin II receptor blocker neprilysin inhibitor (ARNI): new avenues in cardiovascular therapy","volume":"22","author":"Volpe","year":"2015","journal-title":"High Blood Press. Cardiovasc. Prev."},{"key":"10.1016\/j.biopha.2017.04.024_bib0170","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.2337\/diabetes.52.9.2389","article-title":"B-Type natriuretic peptide prevents acute hypertrophic responses in the diabetic rat heart importance of cyclic GMP","volume":"52","author":"Rosenkranz","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2017.04.024_bib0175","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00125-014-3201-4","article-title":"Treatment with brain natriuretic peptide prevents the development of cardiac dysfunction in obese diabetic db\/db mice","volume":"57","author":"Plante","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopha.2017.04.024_bib0180","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ahj.2015.04.007","article-title":"Worsening heart failure during hospitalization for acute heart failure: insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF)","volume":"170","author":"Kelly","year":"2015","journal-title":"Am. Heart J."},{"key":"10.1016\/j.biopha.2017.04.024_bib0185","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1100171","article-title":"Effect of nesiritide in patients with acute decompensated heart failure","volume":"365","author":"O'connor","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2017.04.024_bib0190","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1161\/01.CIR.0000141829.04031.25","article-title":"Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine","volume":"110","author":"Wang","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2017.04.024_bib0195","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1056\/NEJM199703203361203","article-title":"Anaritide in acute tubular necrosis","volume":"336","author":"Allgren","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2017.04.024_bib0200","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1253\/circj.CJ-15-0928","article-title":"Predictors of worsening renal function in patients with acute decompensated heart failure treated by low-Dose carperitide","volume":"80","author":"Kawase","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2017.04.024_bib0205","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1210\/er.2005-0014","article-title":"Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions","volume":"27","author":"Potter","year":"2006","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.biopha.2017.04.024_bib0210","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0014-2999(95)00315-C","article-title":"Neutral endopeptidase inhibition, a new approach in the exploration of diabetic vasculopathy in rats","volume":"285","author":"Chakir","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2017.04.024_bib0215","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1524-475X.2002.10504.x","article-title":"Neutral endopeptidase inhibition in diabetic wound repair","volume":"10","author":"Spenny","year":"2002","journal-title":"Wound Repair Regen."},{"key":"10.1016\/j.biopha.2017.04.024_bib0220","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/jnen\/nlw083","article-title":"Effect of inhibition or deletion of neutral endopeptidase on neuropathic endpoints in high fat Fed\/Low dose streptozotocin-Treated mice","volume":"75","author":"Yorek","year":"2016","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.biopha.2017.04.024_bib0225","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1161\/01.HYP.32.4.778","article-title":"Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus","volume":"32","author":"Tikkanen","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.biopha.2017.04.024_bib0230","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1038\/sj.bjp.0703442","article-title":"Effects of combined neutral endopeptidase 24-11 and angiotensin-converting enzyme inhibition on femoral vascular conductance in streptozotocin-induced diabetic rats","volume":"130","author":"Arbin","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2017.04.024_bib0235","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1042\/cs1040341","article-title":"Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin\u2013angiotensin system","volume":"104","author":"Lassila","year":"2003","journal-title":"Clin. Sci."},{"key":"10.1016\/j.biopha.2017.04.024_bib0240","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/sj.bjp.0704098","article-title":"Acute effect of the dual angiotensin-converting enzyme and neutral endopeptidase 24-11 inhibitor mixanpril on insulin sensitivity in obese Zucker rat","volume":"133","author":"Arbin","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2017.04.024_bib0245","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/00005344-200302000-00015","article-title":"Effects of dual angiotensin-converting enzyme and neutral endopeptidase 24-11 chronic inhibition by mixanpril on insulin sensitivity in lean and obese Zucker rats","volume":"41","author":"Arbin","year":"2003","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.biopha.2017.04.024_bib0250","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0008-6363(03)00544-3","article-title":"Vasopeptidase inhibition prevents nephropathy in Zucker diabetic fatty rats","volume":"60","author":"Sch\u00e4fer","year":"2003","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.biopha.2017.04.024_bib0255","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1463-1326.2008.00924.x","article-title":"Treatment of Zucker diabetic fatty rats with AVE7688 improves vascular and neural dysfunction","volume":"11","author":"Oltman","year":"2009","journal-title":"Diab. Obes. Metab."},{"key":"10.1016\/j.biopha.2017.04.024_bib0260","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s00125-003-1264-8","article-title":"The vasopeptidase inhibitor AVE7688 ameliorates Type 2 diabetic nephropathy","volume":"47","author":"Sch\u00e4fer","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopha.2017.04.024_bib0265","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2337\/db06-1180","article-title":"Treatment of streptozotocin-induced diabetic rats with AVE7688, a vasopeptidase inhibitor effect on vascular and neural disease","volume":"56","author":"Davidson","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2017.04.024_bib0270","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.ejphar.2010.10.047","article-title":"Role of the effect of inhibition of neutral endopeptidase on vascular and neural complications in streptozotocin-induced diabetic rats","volume":"650","author":"Oltman","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2017.04.024_bib0275","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1161\/01.CIR.0000062646.09566.CC","volume":"107","author":"Wang","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2017.04.024_bib0280","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.npep.2009.09.004","article-title":"Altered cardiac bradykinin metabolism in experimental diabetes caused by the variations of angiotensin-converting enzyme and other peptidases","volume":"44","author":"Adam","year":"2010","journal-title":"Neuropeptides"},{"key":"10.1016\/j.biopha.2017.04.024_bib0285","doi-asserted-by":"crossref","first-page":"36A","DOI":"10.1016\/S0895-7061(00)00385-X","article-title":"Effects of omapatrilat on blood pressure and the progression of renal failure in an experimental model of type ii diabetes mellitus","volume":"13","author":"Garcia-Robles","year":"2000","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.biopha.2017.04.024_bib0290","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00125-003-1121-9","article-title":"Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy","volume":"46","author":"Davis","year":"2003","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopha.2017.04.024_bib0295","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ejphar.2005.07.015","article-title":"Vasopeptidase inhibition has beneficial cardiac effects in spontaneously diabetic Goto\u2013Kakizaki rats","volume":"519","author":"Gr\u00f6nholm","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2017.04.024_bib0300","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1097\/01.hjh.0000179765.48324.b4","article-title":"Vascular and renal effects of vasopeptidase inhibition and angiotensin-converting enzyme blockade in spontaneously diabetic Goto-Kakizaki rats","volume":"23","author":"Cheng","year":"2005","journal-title":"J. Hypertens."},{"key":"10.1016\/j.biopha.2017.04.024_bib0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0167-5273(02)00389-3","article-title":"Omapatrilat-the story of overture and octave","volume":"86","author":"Coats","year":"2002","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.biopha.2017.04.024_bib0310","doi-asserted-by":"crossref","first-page":"6722","DOI":"10.1167\/iovs.16-20289","article-title":"Beneficial effects of combined AT1 Receptor\/Neprilysin inhibition (ARNI) versus AT1 receptor blockade alone in the diabetic eye ARNI protects against diabetic retinopathy","volume":"57","author":"Prasad","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.biopha.2017.04.024_bib0315","first-page":"60","article-title":"Risk related to Pre\u2013diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial","author":"Kristensen","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.biopha.2017.04.024_bib0320","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/ejhf.232","article-title":"Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction","volume":"17","author":"Voors","year":"2015","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.biopha.2017.04.024_bib0325","article-title":"Improved insulin sensitivity with angiotensin receptor neprilysin inhibition in individuals with obesity and hypertension","author":"Jordan","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2017.04.024_bib0330","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Collaboration","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2017.04.024_bib0335","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/ncpendmet0638","article-title":"Diabetes and hypertension","volume":"3","author":"Lago","year":"2007","journal-title":"Nat. Clin. Pract. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2017.04.024_bib0340","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/S0140-6736(14)61402-1","article-title":"Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy","volume":"385","author":"Gilbert","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2017.04.024_bib0345","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.2337\/diacare.26.8.2433","article-title":"Heart Failure The frequent, forgotten, and often fatal complication of diabetes","volume":"26","author":"Bell","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2017.04.024_bib0350","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0140-6736(89)90714-9","article-title":"Effects of UK 69 578: a novel atriopeptidase inhibitor","volume":"334","author":"Northridge","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2017.04.024_bib0355","doi-asserted-by":"crossref","first-page":"7580","DOI":"10.1073\/pnas.86.19.7580","article-title":"Protection of atrial natriuretic factor against degradation: diuretic and natriuretic responses after in vivo inhibition of enkephalinase (EC 3. 4. 24. 11) by acetorphan","volume":"86","author":"GRos","year":"1989","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biopha.2017.04.024_bib0360","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/0140-6736(90)90595-V","article-title":"Effect of sinorphan on plasma atrial natriuretic factor in congestive heart failure","volume":"335","author":"Kahn","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2017.04.024_bib0365","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/1755-5922.12053","article-title":"Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat","volume":"32","author":"Dalzell","year":"2014","journal-title":"Cardiovasc. Ther."},{"key":"10.1016\/j.biopha.2017.04.024_bib0370","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1161\/01.CIR.97.23.2323","article-title":"Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo","volume":"97","author":"Ferro","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2017.04.024_bib0375","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s13770-016-9089-y","article-title":"Substance P and thiorphan synergically enhance angiogenesis in wound healing","volume":"13","author":"Um","year":"2016","journal-title":"Tissue Eng. Regen. Med."},{"key":"10.1016\/j.biopha.2017.04.024_bib0380","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/15438600303728","article-title":"Omapatrilat, an angiotensin-converting enzyme and neutral endopeptidase inhibitor, attenuates early atherosclerosis in diabetic and in nondiabetic low-density lipoprotein receptor-deficient mice","volume":"4","author":"Levy","year":"2003","journal-title":"Exp. Diab. Res."},{"key":"10.1016\/j.biopha.2017.04.024_bib0385","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1097\/01.hjh.0000184747.41565.a1","article-title":"Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice","volume":"23","author":"Jandeleit-Dahm","year":"2005","journal-title":"J. Hypertens."},{"key":"10.1016\/j.biopha.2017.04.024_bib0390","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","article-title":"OS Group, Comparison of omapatrilat and enalapril in patients with chronic heart failure the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2017.04.024_bib0395","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/eurheartj\/ehs262","article-title":"Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics","volume":"34","author":"Mangiafico","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2017.04.024_bib0400","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","article-title":"Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised double-blind, placebo-controlled, active comparator study","volume":"375","author":"Ruilope","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2017.04.024_bib0405","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/j.jacc.2015.08.877","article-title":"LCZ696 (Sacubitril\/Valsartan): Can we predict who will benefit?","volume":"66","author":"Dec","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2017.04.024_bib0410","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2017.04.024_bib0415","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.cardfail.2015.06.158","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 is effective across the spectrum of ejection fraction in heart failure with reduced ejection fraction","volume":"21","author":"Solomon","year":"2015","journal-title":"J Cardiac. Fail"},{"key":"10.1016\/j.biopha.2017.04.024_bib0420","first-page":"45","article-title":"Nine new analyses show Novartis\u2019 LCZ696 could change course of heart failure for patients","volume":"22","author":"Carroll","year":"2014","journal-title":"Nine"},{"key":"10.1016\/j.biopha.2017.04.024_bib0425","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1042\/CS20160243","article-title":"Angiotensin II type 2 receptor (AT2R) in renal and cardiovascular disease","volume":"130","author":"Chow","year":"2016","journal-title":"Clin. Sci."},{"key":"10.1016\/j.biopha.2017.04.024_bib0430","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1592\/phco.22.13.1173.33517","article-title":"Angiotensin II receptor blocker-Associated angioedema: on the heels of ACE inhibitor angioedema","volume":"22","author":"Abdi","year":"2002","journal-title":"Pharmacother"},{"key":"10.1016\/j.biopha.2017.04.024_bib0435","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1016\/j.ddstr.2013.11.002","article-title":"Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure","volume":"9","author":"Langenickel","year":"2013","journal-title":"Drug Discov. Today Ther. Strateg."},{"key":"10.1016\/j.biopha.2017.04.024_bib0440","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1385\/JMN:22:1-2:5","article-title":"Neprilysin regulates amyloid \u03b2 peptide levels","volume":"22","author":"Marr","year":"2004","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.biopha.2017.04.024_bib0445","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.neubiorev.2016.03.005","article-title":"Diabetes and Alzheimer\u2019s disease crosstalk","volume":"64","author":"Baglietto-Vargas","year":"2016","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.biopha.2017.04.024_bib0450","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa1409077","article-title":"Neprilysin inhibition for heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2017.04.024_bib0455","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2017.04.024_bib0460","first-page":"129","article-title":"Brain-heart interactions and circadian rhythms in chronic heart failure (Homage to dr. franz halberg on the 2nd anniversary of his death on 9th june 2013)","volume":"7","author":"Singh","year":"2015","journal-title":"World Heart J"},{"key":"10.1016\/j.biopha.2017.04.024_bib0465","first-page":"209","article-title":"Can brain-derived neurotrophic factor modulate cardiometabolic risk for prevention of vascular disease?","volume":"7","author":"Singh","year":"2015","journal-title":"World Heart J."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332217303505?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332217303505?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T13:29:42Z","timestamp":1656768582000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332217303505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":93,"alternative-id":["S0753332217303505"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2017.04.024","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neprilysin inhibitors: A new hope to halt the diabetic cardiovascular and renal complications?","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2017.04.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}